DPP-4I not tied to increased risk of acute pancreatitis in seniors

April 10, 2018

(HealthDay)—For older adults, dipeptidyl peptidase 4 inhibitors (DPP-4Is) are not associated with increased risk of acute pancreatitis, according to a study published online April 4 in Diabetes Care.

Jin-Liern Hong, Ph.D., from the University of North Carolina at Chapel Hill, and colleagues examined the risks of among U.S. Medicare beneficiaries, aged 66+ years, initiating DDP-4Is versus thiazolidinediones or sulfonylureas. Participants had no history of pancreatic disease or alcohol-related diseases.

The researchers found that the risk of acute pancreatitis was not increased comparing 49,374 DPP-4I initiators with 132,223 sulfonylurea initiators (weighted hazard ratio, 1.01; 95 percent confidence interval, 0.83 to 1.24) and comparing 57,301 DPP-4I initiators with 32,612 thiazolidinedione initiators (weighted hazard ratio, 1.11; 95 percent confidence interval, 0.76 to 1.62). The association was not modified by age and sex. Acute pancreatitis incidence was increased for DDP-4I and sulfonylurea initiators but not for thiazolidinedione initiators (2.3 and 2.4 versus 1.5 per 1,000 person-years, respectively), among patients with cardiovascular disease (CVD). The risk of acute pancreatitis was increased among patients with CVD taking DPP-4Is versus thiazolidinediones (weighted hazard ratio, 1.84; 95 percent confidence interval, 1.02 to 3.35), but not compared to sulfonylureas.

"Our study provides evidence that DPP-4I is not associated with an increased risk of acute pancreatitis in overall," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: DPP-4i treatment doesn't up MI, stroke risk in seniors

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

DPP-4i treatment doesn't up MI, stroke risk in seniors

February 25, 2017
(HealthDay)—For older U.S. Medicare beneficiaries, dipeptidyl peptidase-4 inhibitors (DPP-4i) treatment is not associated with increased cardiovascular (CV) risk relative to sulfonylureas (SU) and thiazolidinediones (TZD), ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

September 22, 2014
(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according to a study ...

Gliptin treatment tied to higher risk of acute pancreatitis

September 27, 2016
(HealthDay)—Gliptin treatment is associated with increased acute pancreatitis risk, according to research published online Sept. 22 in Diabetes Care.

Early treatment decisions can alter the course of care for acute pancreatitis patients

February 9, 2018
Management and treatment decisions made within the first 48 to 72 hours of hospital admission for acute pancreatitis patients can significantly alter the course of disease and duration of hospitalization. A new clinical guideline ...

CV risk not significantly different for GLP-1 receptor agonists

April 13, 2016
(HealthDay)—There are no significant differences in occurrence of cardiovascular disease (CVD) tied to treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) compared with dipeptidyl peptidase-4 inhibitors ...

PPI-gastric cancer link remains after H. pylori eradication

November 2, 2017
(HealthDay)—Long-term proton pump inhibitor (PPI) use is associated with increased risk of gastric cancer (GC) even after Helicobacter pylori (HP) eradication therapy, according to a study published online Oct. 31 in Gut.

Recommended for you

Researchers cure type 2 diabetes and obesity in mice using gene therapy

July 10, 2018
A research team from the UAB led by Professor Fatima Bosch has managed to cure obesity and type 2 diabetes in mice using gene therapy.

Human clinical trial reveals verapamil as an effective type 1 diabetes therapy

July 9, 2018
Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent ...

New targets found to reduce blood vessel damage in diabetes

July 9, 2018
In diabetes, both the tightly woven endothelial cells that line our blood vessels and the powerhouses that drive those cells start to come apart as early steps in the destruction of our vasculature.

Insurance gaps linked to five-fold rise in hospital stays for adults with type 1 diabetes

July 9, 2018
For a million American adults, living with type 1 diabetes means a constant need for insulin medication, blood sugar testing supplies and specialized care, to keep them healthy and prevent a crisis that could end up in an ...

Abnormal branched-chain amino acid breakdown may raise diabetes risk

July 5, 2018
In the U.S., about five out of 100 expectant mothers develop gestational diabetes mellitus (GDM), a temporary form of diabetes in which hormonal changes disrupt insulin function. Although GDM is often symptomless and subsides ...

Air pollution contributes significantly to diabetes globally

June 30, 2018
New research links outdoor air pollution—even at levels deemed safe—to an increased risk of diabetes globally, according to a study from Washington University School of Medicine in St. Louis and the Veterans Affairs (VA) ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.